Navigation Links
Raven biotechnologies and Bioprocessing Technology Institute Announce Collaboration to Advance Discovery of Stem Cell Antibodies
Date:4/4/2008

e separation of stem cell populations for BTI's cell therapy work."

About Bioprocessing Technology Institute (BTI)

Bioprocessing Technology Institute (BTI) is a member of the Agency for Science, Technology and Research (A*STAR). Established in 1990 as the Bioprocessing Technology Unit, it was renamed the Bioprocessing Technology Institute (BTI) in 2003. The research institute's mission is to develop manpower capabilities and establish cutting-edge technologies relevant to the bioprocessing community. Some of the key research areas include expression engineering, animal cell technology, stem cell research, microbial fermentation, downstream purification and analytics. More information on BTI can be found at http://www.bti.a-star.edu.sg.

About Raven biotechnologies

Raven biotechnologies, inc. (http://www.ravenbio.com) is a privately held biotechnology company focused on the development of monoclonal antibody therapeutics for treating cancer. Raven's lead product candidate, RAV12, targets adenocarcinomas and is in clinical development for the treatment of gastrointestinal and other cancers. Raven's discovery process simultaneously identifies cell-surface drug targets and the antibody therapeutics to regulate them. Our focus on biological function allows us to rapidly identify novel target antigens and therapeutic candidates in their native configuration in the intact cell membrane. Our integrated approach is based on proprietary methods for optimizing the production of MAbs targeting cell-surface proteins, including the use of human tissue-specific progenitor and tumor stem cell lines developed at Raven.

To date Raven has identified multiple candidate therapeutic MAbs for many cancer indications including lung, colon, pancreatic, prostate, breast and ovarian cancer.


'/>"/>
SOURCE Raven biotechnologies, inc.; Bioprocessing TechnologyInstitute
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. VaxGen and Raven Terminate Merger Agreement
2. Arpida Submits New Drug Application for Intravenous Iclaprim for Treatment of Skin Infections
3. Raven Announces RAV12 Phase 1/2a Study Results To Be Presented at ASCO
4. Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim
5. Raven biotechnologies to Provide Updates on Oncology Pipeline With Four AACR Presentations
6. VaxGen and Raven Announce Form S4 Registration Statement Declared Effective
7. Lentigen Appoints Tim Ravenscroft as Chief Executive Officer
8. First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP
9. Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
10. Positive Outcome of Drug-Drug Interaction Trial With Intravenous Iclaprim
11. Epeius Biotechnologies Awarded U.S. Patent for Targeted Injectable Gene Delivery In Vivo
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Md. (PRWEB) January 22, 2015 ... its new UV-1280 multipurpose UV-visible spectrophotometer. Offering wavelength ... high-quality instrument is ideal for applications in a ... life science. , The user-friendly UV-1280 enables intuitive ...
(Date:1/22/2015)... CAMBRIDGE, Mass (PRWEB) January 21, 2015 Cambridge ... Semantic Web technology, today announced that 2014 was a record-breaking ... expanding the capabilities of the Anzo Smart Data Platform and ... discover and utilize insights from diverse data which led to ...
(Date:1/22/2015)... Pipette.com has added the Eppendorf Centrifuge ... of Eppendorf products. , The Eppendorf Centrifuge 5424/5424 R ... R and receive the following:, ,     Free ... Eppendorf Reference 2 ,     3 Free boxes ...
(Date:1/22/2015)... Selexis SA, a serial innovation company with proven ... for drug discovery to commercial manufacturing, announced today all ... Sequencing (NGS) data packages. The NGS analysis of ... the integrity of the gene, validation of the left ...
Breaking Biology Technology:Shimadzu’s New Monitored Single-Beam UV-Vis Spectrophotometer Offers Comprehensive Measurement Options in a Compact Body 2Cambridge Semantics Announces Record Results for 2014 2Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2
... BASEL, Switzerland, March 26 Roche (SWX: ROG.VX; RO.S, ... Investments USA Inc., completed its tender offer for the ... ). The offer expired at midnight, New York City ... total of approximately 395.7 million shares of Genentech common ...
... Hello, , The investor ... has,been webcasted. The presentation is available in English from ... , a2e0f120f7f05e9c&portal_id=55a3fb63ef049550bc3b4d09baf7bf5e , (Due ... necessary to copy and paste,this hyperlink into your Internet ...
... BROOMFIELD, Colo., March 25 Accera, Inc., a biotechnology ... disorders, today announced that the company will be participating ... Founder, President and CEO, will speak at the 2nd ... a.m. EDT at the Sheraton Boston Hotel in Boston, ...
Cached Biology Technology:Roche Completes Tender Offer for Genentech 2Roche Completes Tender Offer for Genentech 3Accera, Inc. to Present at Upcoming Investor Conferences 2
(Date:12/17/2014)... Valencell, a leader in performance biometric data sensor technology, ... such as Intel, Jabra, Atlas, and Scosche to develop ... products will be showcased at CES 2015, taking place ... "Our partners choose PerformTek biometrics, because ...
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of the ... offering. One major trend emerging in ... Multimodal biometric systems utilize more than one characteristic of ...
(Date:12/10/2014)... , Dec. 9, 2014  Wake Forest Baptist Medical Center ... its School of Medicine. Funding for this $50 million capital ... be publicly launched next summer. The medical ... R.J. Reynolds Tobacco Company complex, adjacent to 525@vine in Wake ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... PHILADELPHIA Results of a new study confirm trends ... certain cancers and worse cancer outcomes if they live in ... their homelands. "Hispanics are not all the same ... M.D., Ph.D., M.Sc., researcher in the Department of Epidemiology at ...
... breast or ovarian cancer are choosing to undergo surgery as ... a report in Cancer Epidemiology, Biomarkers & Prevention , ... "Women have their breasts or ovaries removed based on their ... a genetic test result and can take more than seven ...
... Most people who carry a genetic mutation for a ... phenomenon that has puzzled scientists since the first genetic ... The Feinstein Institute for Medical Research have figured out ... the disorder they have an additional lesion that ...
Cached Biology News:Moving to the US increases cancer risk for Hispanics 2Moving to the US increases cancer risk for Hispanics 3Women often opt to surgically remove their breasts, ovaries to reduce cancer risk 2Women often opt to surgically remove their breasts, ovaries to reduce cancer risk 3Abnormal brain circuits may prevent movement disorder 2
Polyclonal Antibody to AHI1 / Jouberin...
Peptide-affinity Purified Polyclonal Antibody to Purinergic Receptor P2Y12...
Purified anti-PXR...
Goat polyclonal to MLH3 Immunogen: Synthetic peptide: RQSLQQSMPPCEPP (Human) from C Terminus of the protein sequence according to NP_055196....
Biology Products: